PVmed Raises US $14 Million Series A Funding from Cherami, Philips, JHF, COCOCAPITAL, and Strategy Capital

Supports Rapid Expansion of PVmed’s AI Oncology Product Portfolio

Guangzhou, China, December 22, 2022 /PRNewswire/ — Perception Vision Medical Technologies Co., Ltd. (PVmed) is a global artificial intelligence (AI) cancer treatment company that Guangzhou, Chinasecured the United States $14 million (RM100 million) has received Series A funding from investors including Cherami Investment Group, Philips, JHF Investment, COCOCAPITAL Corporation and Strategy Capital. The funding will allow the company to further develop his AI cancer treatment product portfolio and ecosystem. It will also accelerate the adoption of the company’s AI-defined cancer surgery and radiotherapy workflows and his software and hardware products by hospitals and medical technology companies.

shaolin wayGeneral Partner of Cherami, and Bill ChenSenior Vice President of Philips Greater China and General Manager of Philips Precision Diagnostics Business Group will join PVmed’s Board of Directors.

Since its release in May 2017, PVmed has developed a portfolio of AI-defined cancer treatment workflow products that are of great interest to surgical oncologists, radiation oncologists, and medical physicists. These products automatically process and prepare three-dimensional (3D) computed tomography scans (CT) and magnetic resonance imaging (MR) data to help physicians diagnose cancers (lung, breast, nasopharyngeal, pediatric) Cervical cancer, rectal cancer, etc.) to help plan and treat. Cancer) is more accurate and much faster. For example, the time required for a physician to outline an organ at risk (OAR) using PVmed’s auto-contour technology is reduced from 1-2 hours to less than 5 minutes, a 10-fold reduction.

PVmed products are currently installed in over 200 hospitals. China We have now treated over 200,000 cancer patients. The company recently signed a sales and partnership agreement with the Tianjin Medical University Cancer Institute and Hospital, one of China’s largest cancer centers. Chinaperforms 32,000 surgeries and receives 1.3 million outpatient visits annually.

Said Chengyang ShuPVmed’s President and Co-Chair, said, “We are very pleased to receive this funding from these leading Chinese and global financial and corporate investors. We also appreciate the strategic insight and We are also excited about the resources. We now have thousands of physicians. AI defined as we are benefiting hundreds of thousands of cancer patients using PVmed’s AI cancer care workflow products. It is clear that the age of cancer treatment procedures has arrived.”

Xu adds: “We are increasingly seeing AI models trained using the results of experienced physicians, providing physicians with accurate 3D contextual and targeted information about organs and tumors at each stage of surgery, Empowering a broader range of physicians: Hospitals that have adopted AI-defined cancer care procedures for their patients and physicians will see increased physician productivity, reduced operating costs, and physicians can reduce average It saves 1.5 hours, totaling 20% ​​to 40% less physician time per patient treatment.”

Said shaolin way“At Cherami, we share PVmed’s vision of using AI to enable physicians to serve more patients and provide better care. Patients benefit immensely when they have access, but AI-defined diagnostic and therapeutic techniques are even more important for those who do not have easy access to basic medical facilities. Nairobi in (UoN) Kenya Established UoN Cherami Cancer Research and Training Hospital. With support and encouragement from the PVmed team, he has a clear vision to make this institute a port for the introduction of his AI diagnostics, therapeutics, and other digital healthcare tools. AfricaSo you can reach previously unattainable problems and solve previously unsolvable problems. ”

Said Bill Chen“Philips works closely with our local partners to provide the best possible experience for our customers and patients. ChinaPVmed is one of the key innovation partners in the oncology area. Since 2021, the companies have co-developed locally relevant radiation oncology solutions to provide more accurate and personalized care to cancer patients. We also collaborate in market development to influence the market. ”

PVmed’s AI cancer treatment portfolio includes three solutions:

The company has 6 medical device certifications (2 NMPA Class III, 1 FDA 510k, and three NMPA Class II), 92 invention patents, and 41 software copyrights for medical institutions, device manufacturers, and technology service providers worldwide. We have partnerships with many leading hospitals in China and Singapore and strategic cooperation agreements with Philips, Elekta, Noah Medical, RADLogics, Neusoft, MinFound and Kanda Medical Equipment.

For more information about PVmed, please visit www.pvmedtech.com/en/.

Cerami Investment Group: officially established August 1, 2013head office Guangzhou, China, Cherami Investment Group’s vision is to ‘create value from wealth’. The company covers multiple business areas such as securities, equities and international industrial investment.Established more than 10 branches in China We started to respond to overseas markets, first expanding our business to African countries. The company’s private equity investments focus on deep tech industries such as new energy vehicles, new semiconductor materials and healthcare. Cherami’s investment projects include Contemporary Amperex Technology, CALB, Ronbay Technology, Shanghai HIUV New Materials, Xi’an Sinofuse Electric, Semiconductor Manufacturing Electronics (ShaoXing) Corporation, Maxio Technology, GenFleet Therapeutics, and GenEros BioPharma.

Phillips: Royal Phillips of Netherlands is a leading health technology company dedicated to improving people’s health and enabling better outcomes across the health continuum, from healthy living and prevention to diagnostics, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insight to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring, health informatics, consumer health and home care.

Institutional investment: Founded in 2010, JHF Investments has many years of private equity investment experience, primarily focused on start-ups and high-growth companies. Joe Licia, a prominent investor and chairman of the Angel Investor Coalition, founded the company. His team includes alumni from Tsinghua University, Fudan University, Central University of Finance and Economics, and other leading international universities. The company has made many investments in the medical industry, including Huilun Pharma, Xeno Life Science, Amplicon Gene, GX Pharma and Deviceland.

Coco Capital Co., Ltd.: Founded in 2015, COCOCAPITAL Corporation is a fund management firm focused on providing top quality capital services to innovative start-ups including venture capital funds, private equity investment funds, industrial investments and M&A funds. . Major investors include state-owned enterprise groups, listed companies, government guidance funds, and professional funds of funds. Its main areas of investment are intelligence and the enterprise Internet. Wei Feng, a founding partner of Coco Capital, has over 10 years of hands-on experience in venture capital.he won best venture capitalist China 2019 and best angel investor China 2018 by Forbes. Investments include Will Semiconductor, Shanghai Newtouch Software, Doright and others.

Strategic Capital: Strategy Capital is a cutting-edge investment firm focused on next-generation information technology, including artificial intelligence, and related advanced materials technology. The firm employs a research-driven strategy, emphasizes industry expertise, and carefully and meticulously selects high-quality projects with solid growth potential for its investment portfolio. Strategy Capital is committed to providing industry management, capital management, human resources and other comprehensive services and deep empowerment to clients throughout the entire business lifecycle. Recent related investments include Shenzhen Zvit Technology, Suzhou Rochu Robotics, Shenzhen Breax Biological Technology and Shenzhen Vispek Technology.



View original content: https://www.prnewswire.com/news-releases/pvmed-raises-us-14-million-series-a-funding-from-cherami-philips-jhf-cococapital-and-strategy- capital-301709483.html

SOURCE Perception Vision Medical Technologies Co., Ltd.

Source link

Leave a Reply

%d bloggers like this: